<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751777</url>
  </required_header>
  <id_info>
    <org_study_id>ELT207</org_study_id>
    <nct_id>NCT00751777</nct_id>
  </id_info>
  <brief_title>Traveler's Diarrhea (TD) Automated Process</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the immune responses and safety following a two vaccination regimen
      by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or
      placebo patches.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</measure>
    <time_frame>Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</measure>
    <time_frame>Day 14, Day 21, Day 28, Day 35, Day 90, Day 194</time_frame>
    <description>GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</measure>
    <time_frame>Day 14, Day 21, Day 28, Day 35, Day 90, Day 194</time_frame>
    <description>Definition of SCR:
Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline
Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Duration of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Prevention of Travelers' Diarrhea</condition>
  <arm_group>
    <arm_group_label>Group 1: 37.5 µg LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 subjects will receive a two vaccination regimen with a LT patch.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 0 µg LT patch (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 subjects will receive a two vaccination regimen with a placebo patch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heat-labile enterotoxin of E. coli (LT)</intervention_name>
    <description>Travelers' Diarrhea Vaccine System</description>
    <arm_group_label>Group 1: 37.5 µg LT patch</arm_group_label>
    <other_name>TD Vaccine System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Travelers' Diarrhea Vaccine System</description>
    <arm_group_label>Group 2: 0 µg LT patch (placebo)</arm_group_label>
    <other_name>TD Vaccine System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males or females, 18-64 years of age (inclusive) at the planned start of
             the study (first vaccination on Day 0)

          -  Signed Informed Consent

          -  Women who are not post-menopausal or surgically sterile must have a negative
             serum/urine pregnancy test at screening and within 24 hours of each vaccination with
             understanding (through Informed Consent process) to not become pregnant and to employ
             an effective form of birth control for the duration of the study. Acceptable forms of
             birth control are: abstinence, hormonal contraceptives (oral, injectable, implant,
             patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide),
             and IUD.

        Exclusion Criteria:

          -  Laboratory abnormalities [as determined by the Toxicity Grading Scale (grade 1 4)] at
             laboratory screening

          -  Abnormalities at physical examination [as determined by the Toxicity Grading Scale
             (grade 1-4)]

          -  Known allergies to any component of the vaccine

          -  Known allergies to adhesives

          -  Participated in research involving investigational product within 30 days before
             planned date of first vaccination or within 90 days after first vaccination

          -  Donated blood or blood products such as plasma within 30 days prior to planned date of
             first vaccination or within 90 days after first vaccination

          -  Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu,
             Berna Biotech, Ltd

          -  Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™)

          -  History of diarrhea while traveling in a developing country within the last year

          -  History of abdominal surgery (excluding C-section, hysterectomy, cosmetic surgery,
             liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries
             not pertaining to gastrointestinal problems) or history of, or recent acute
             gastrointestinal illness

          -  Positive serology for HIV-1, HIV-2, HBsAg, or HCV

          -  Medical history of acute or chronic skin disease at vaccination area(s)

          -  Active skin allergy

          -  Signs of acute skin infection, sunburn or skin abnormalities at the vaccination
             area(s) including fungal infections, severe acne, or active contact dermatitis, or a
             history of keloid formation

          -  Excessively hirsute and unwilling to clip hair at the vaccination area(s)

          -  Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent
             appropriate dermatologic monitoring of the vaccination site(s)

          -  Fever greater than or equal to 38.0°C (100.4°F) at the time of planned vaccination

          -  Women who are pregnant or breastfeeding

          -  Acute illness at screening and unresolved at time of planned vaccination

          -  Employee of the investigational site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sheldon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <results_first_submitted>January 30, 2014</results_first_submitted>
  <results_first_submitted_qc>March 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 37.5 µg LT Patch</title>
          <description>heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 0 µg LT Patch (Placebo)</title>
          <description>Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70">Day 380: study completion for LT group</participants>
                <participants group_id="P2" count="36">Day 194: study completion for placebo group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) Population: all study subjects who were consented, randomized, and had a baseline serology</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 37.5 µg LT Patch</title>
          <description>heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 0 µg LT Patch (Placebo)</title>
          <description>Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="10.2"/>
                    <measurement group_id="B2" value="35.3" spread="13.0"/>
                    <measurement group_id="B3" value="34.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</title>
        <time_frame>Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194</time_frame>
        <population>Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 37.5 µg LT Patch</title>
            <description>heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 0 µg LT Patch (Placebo)</title>
            <description>Placebo: Travelers' Diarrhea Vaccine System</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</title>
          <population>Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433" lower_limit="349" upper_limit="536"/>
                    <measurement group_id="O2" value="401" lower_limit="291" upper_limit="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4478" lower_limit="3250" upper_limit="6169"/>
                    <measurement group_id="O2" value="491" lower_limit="304" upper_limit="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9108" lower_limit="6792" upper_limit="12213"/>
                    <measurement group_id="O2" value="462" lower_limit="298" upper_limit="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13412" lower_limit="10420" upper_limit="17264"/>
                    <measurement group_id="O2" value="373" lower_limit="255" upper_limit="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15024" lower_limit="11893" upper_limit="18979"/>
                    <measurement group_id="O2" value="384" lower_limit="271" upper_limit="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6824" lower_limit="5553" upper_limit="8385"/>
                    <measurement group_id="O2" value="156" lower_limit="115" upper_limit="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2489" lower_limit="1966" upper_limit="3152"/>
                    <measurement group_id="O2" value="100" lower_limit="71" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch</title>
        <time_frame>7 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear</title>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Duration of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group</title>
        <time_frame>13 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</title>
        <description>GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.</description>
        <time_frame>Day 14, Day 21, Day 28, Day 35, Day 90, Day 194</time_frame>
        <population>Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 37.5 µg LT Patch</title>
            <description>heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 0 µg LT Patch (Placebo)</title>
            <description>Placebo: Travelers' Diarrhea Vaccine System</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</title>
          <description>GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.</description>
          <population>Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.</population>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFR - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.4" upper_limit="14.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.7" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="15.2" upper_limit="29.2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.7" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="23.5" upper_limit="41.0"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.6" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="26.6" upper_limit="45.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.6" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR - Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="12.4" upper_limit="20.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.3" upper_limit="7.5"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</title>
        <description>Definition of SCR:
Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline
Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline</description>
        <time_frame>Day 14, Day 21, Day 28, Day 35, Day 90, Day 194</time_frame>
        <population>Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 37.5 µg LT Patch</title>
            <description>heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 0 µg LT Patch (Placebo)</title>
            <description>Placebo: Travelers' Diarrhea Vaccine System</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo</title>
          <description>Definition of SCR:
Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline
Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline</description>
          <population>Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O2" value="9" lower_limit="2" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="80" upper_limit="95"/>
                    <measurement group_id="O2" value="9" lower_limit="2" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="6" lower_limit="1" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR - Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="9" lower_limit="2" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 37.5 µg LT Patch</title>
          <description>heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 0 µg LT Patch (Placebo)</title>
          <description>Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Application site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head Clinical Development</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>0043120620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

